Risk stratification of acute coronary syndrome, especially myocardial infarction or angina pectoris, by in vitro determination of provasopressin or its fragments or partial peptides

摘要

A risk stratification method for acute coronary syndrome involves determination of a marker (I) selected from provasopressin (pro-AVP) and its fragments or partial peptides (especially copeptin (Ia) or neurophysin II) by in vitro diagnostic methods. Independent claims are included for: (1) methods for in vitro early or differential diagnosis or prognosis of acute coronary syndrome, myocardial infarction or angina pectoris, involving determination of (I) in a test patient; (2) the use of (I) in the risk stratification of acute coronary syndrome, myocardial infarction or angina pectoris and/or for early or differential diagnosis or prognosis of myocardial infarction or angina pectoris; (3) the use of (I) in combination with a natriuretic protein (II) for the diagnosis of acute coronary syndrome, myocardial infarction or angina pectoris; (4) a kit for risk stratification of acute coronary syndrome, myocardial infarction or angina pectoris, containing reagents for detection of (I) and optionally inflammatory, cardiovascular, neurohormonal and/or ischemic markers (III), together with auxiliaries; (5) diagnostic apparatus (no details given) for carrying out the in vitro diagnostic tests; and (6) a kit for diagnosis of acute coronary syndrome, myocardial infarction or angina pectoris, containing reagents for detection of (I), (II) and optionally (III), together with auxiliaries.